Superworth

Maxcyte EPS MXCT

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
−$0.33
Latest quarter, Q2 FY26
−$0.08
Fiscal year 2025
−$0.43

Maxcyte's earnings per share was −$0.33 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.08.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.43n/a
FY2024−$0.39n/a
FY2023−$0.37n/a
FY2022−$0.23n/a
FY2021−$0.22n/a
FY2020−$0.17n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.08n/a−$0.33
Q1 FY26−$0.04n/a−$0.37
Q4 FY25−$0.09n/a−$0.43
Q3 FY25−$0.12n/a−$0.44
Q2 FY25−$0.12n/a−$0.43
Q1 FY25−$0.10n/a−$0.40
Q4 FY24−$0.10n/a−$0.39
Q3 FY24−$0.11n/a−$0.34
Q2 FY24−$0.09n/a−$0.34
Q1 FY24−$0.09n/a−$0.35
Q4 FY23−$0.05n/a−$0.37
Q3 FY23−$0.11n/a−$0.37

Against its peers

Companies in Healthcare nearest Maxcyte's size, closest first, today.

CompanyEPS, 12 monthsGrowth
MXCTMaxcyte−$0.33
PDEXPro DEX$4.11+52% a year
PLXProtalix BioTherapeutics$0.23+283% a year
NATRNatures Sunshine Products$1.01+36% a year
KEQUKewaunee Scientific$2.76−33% a year
ELMDElectromed$1.31+56% a year
ICCCImmucell$0.08−58% a year
UTMDUtah Medical Products$3.28−12% a year
INFUInfuSystem$0.41+78% a year
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
Peer median$0.71

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Maxcyte

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.